Show results for
Refine by
Immunotherapy Equipment & Supplies In Kiribati
119 equipment items found
Manufactured by:MedGenome Inc. based inCounty of New Castle, DELAWARE (USA)
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the treated ...
Manufactured by:AJ Vaccines A/S based inKøbenhavn, DENMARK
VesiCulture (BCG Culture) For the treatment of Bladder ...
Manufactured by:Diamyd Medical AB based inStockholm, SWEDEN
Diamyd® is a suspension for injection containing the active pharmaceutical ingredient GAD65 mixed with the vaccine adjuvant Alhydrogel (alum). The human recombinant protein GAD65 is manufactured in insect cells in a well-controlled GMP process. The manufacturing process is developed for late phase clinical use. A new manufacturing facility is being set up by Diamyd Medical in Umeå, ...
by:Vaccitech plc based inOxford, UNITED KINGDOM
The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2), and are in the group E simian adenovirus family, similar to the widely-studied chimpanzee adenovirus 63. These viruses have been engineered to be replication deficient and can be manufactured in well-established HEK293 cell lines containing the adenoviral E1 ...
by:Metaclipse Therapeutics Corporation based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a patient’s tumor tissue that Metaclipse modifies with a ‘protein transfer’ method using proven ...
by:Metaclipse Therapeutics Corporation based inAtlanta, GEORGIA (US) (USA)
Influenza (Target age 65+) and Influenza+ SARS-C0V-2 ...
Manufactured by:Treos Bio Limited based inLondon, UNITED KINGDOM
Off-the-shelf products contain 6-12 shared tumor-specific antigen derived peptides optimized for a population. They are personalized with a candidate companion diagnostic test (CDx). In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high proportion of patients, without need of biopsy. Phase 1 clinical study ...
Manufactured by:Intrommune Therapeutics based inNew York, NEW YORK (USA)
Intrommune has developed a novel drug delivery platform—oral mucosal immunotherapy (OMIT)—for the treatment of food allergies. Therapeutic agents are embedding in fully functioning toothpaste so that treatment can be conveniently administered during a patient’s daily toothbrushing ...
by:NEC OncoImmunity AS based inOslo, NORWAY
This plus many other breakthroughs in immuno-oncology and the rapid advances in next generation sequencing (NGS), opens up exciting new opportunities to harness neoantigens for their therapeutic and biomarker potental in cancer immunotherapy. NEC OncoImmunty uses a powerful artificial intelligence (AI) engine to predict from next generation sequencing data, true neoantigens for ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), ...
Manufactured by:Treos Bio Limited based inLondon, UNITED KINGDOM
PEPI Panel – A unique approach for personalized cancer immunotherapy generation. Our Peptide Library (PEPI Panel) currently contains 3,286 proprietary, immunogenic peptide fragments from 184 tumor antigens associated with 19 cancer indications that induce immune responses in the largest subpopulation of subjects, based on HLA genotype (both class I and II) of 16,000 ...
Manufactured by:Octapharma AG based inLachen, SWITZERLAND
Liquid, ready-to-use subcutaneous immunoglobulin (SCIg). ...
Manufactured by:Octapharma AG based inLachen, SWITZERLAND
Liquid, ready-to-use intravenous immunoglobulin (IVIg). Indication: To treat patients that require replacement of antibodies to help provide protection against some infections. For treatment of some autoimmune disorders (diseases where the immune system is overactive). Panzyga® can only be obtained on a doctor’s ...
Manufactured by:Octapharma AG based inLachen, SWITZERLAND
Liquid, ready-to-use subcutaneous immunoglobulin ...
Manufactured by:Octapharma AG based inLachen, SWITZERLAND
octagam® 5% (50 mg/ml), Human Normal Immunoglobulin. octagam® 10% (100 mg/ml), Human Normal Immunoglobulin. Liquid, ready-to-use intravenous immunoglobulin ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse. Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
A new generation of multifunctional oncolytic virus, TG6002 has been designed to combine the mechanism of oncolysis (targeted destruction of the cancer cell) with the production of chemotherapy (5-FU), directly into the ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 ...
by:Enveric Biosciences, Inc. based inNaples, FLORIDA (USA)
Enveric Biosciences seeks to advance novel combinations of CBD with chemotherapeutic agents and immunotherapies. Preclinical data suggests combination therapies may improve the activity of certain chemotherapies or cancer immunotherapies, potentially enabling more potent or longer-lasting therapeutic effects. In addition, combination therapies may allow for the ...